GlassScriptPhysician profile
Bruce A Phillips
NPI 1922121748
$3,366.04
in general payments reported to CMS, 2019-2025
28 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $585 · 2021: $742 · 2022: $345 · 2023: $595 · 2024: $450 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $518.96 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $443.34 | 2020-2025 | Repatha, Evenity, Prolia |
| Novo Nordisk INC | $272.92 | 2019-2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $253.84 | 2019-2022 | |
| Glaxosmithkline, LLC. | $248.54 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Eisai INC. | $195.75 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $194.71 | 2019-2023 | Qelbree |
| Abbvie INC. | $187.62 | 2021-2025 | |
| Pfizer INC. | $158.08 | 2020-2024 | |
| Currax Pharmaceuticals LLC | $129.32 | 2019-2022 | |
| Lilly USA, LLC | $116.56 | 2020-2023 | Mounjaro, Trulicity |
| Otsuka America Pharmaceutical, INC. | $85.69 | 2024-2025 | Rexulti |
| Bausch Health US, LLC | $84.59 | 2021-2025 | Wellbutrin, Aplenzin |
| Idorsia Pharmaceuticals US INC | $61.14 | 2022-2025 | Quviviq, Quviviq |
| Genentech USA, INC. | $54.24 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $50.62 | 2020-2021 | |
| Cleerly, INC. | $42.03 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Biohaven Pharmaceuticals, INC. | $38.96 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.74 | 2022 | |
| Arbor Pharmaceuticals, INC. | $30.84 | 2019-2021 | |
| Shire North American Group INC | $28.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.01 | 2020 | |
| Millicent US INC | $21.70 | 2020 | |
| Azurity Pharmaceuticals, INC. | $21.17 | 2023 | Edarbi |
| Dermira, INC. | $19.96 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.79 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.76 | 2025 | Nuzyra |
| Allergan, INC. | $12.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.